

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Pillar Invest Corp</u> (Last) (First) (Middle) PILLAR INVEST OFFSHORE SAL STARCO CTR, BLOC B, 3RD FLOOR, OMAR DAOUK STREET (Street) BEIRUT M8 2020-3313 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>IDERA PHARMACEUTICALS, INC. [IDRA]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 04/17/2020	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	04/17/2020		j ⁽¹⁾		46,304	D	\$0.00	5,427,697	I	By Pillar Partners Foundation, L.P. See Footnotes ⁽¹⁾⁽³⁾
Common Stock	04/17/2020		j ⁽¹⁾		103,891	D	\$0.00	1,288,368	I	By Pillar Pharmaceuticals 6, L.P. See Footnotes ⁽²⁾⁽³⁾
Common Stock								21,100	I	By Pillar Pharmaceuticals I, L.P. See Footnote ⁽³⁾
Common Stock								20,820	I	By Pillar Pharmaceuticals II, L.P. See Footnote ⁽³⁾
Common Stock								29,998	I	By Pillar Pharmaceuticals III, L.P. See Footnote ⁽³⁾
Common Stock								1,000	I	By Pillar Pharmaceuticals IV, L.P. See Footnote ⁽³⁾
Common Stock								25,000	I	By Pillar Pharmaceuticals V, L.P. See Footnote ⁽³⁾
Common Stock								6,724	I	By Youssef El Zein See Footnote ⁽³⁾
Common Stock								190,117	I	By Abude Umari See Footnotes ⁽³⁾⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

--

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Deemed Execution Date, if any (Month/Day/Year)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

1. Name and Address of Reporting Person*
[Pillar Invest Corp](#)
 (Last) (First) (Middle)
 PILLAR INVEST OFFSHORE SAL STARCO CTR,
 BLOC B, 3RD FLOOR, OMAR DAOUK STREET

(Street)
 BEIRUT M8 2020-3313
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
[Pillar Partners Foundation, L.P.](#)
 (Last) (First) (Middle)
 PILLAR INVEST OFFSHORE SAL STARCO CTR,
 BLOC B, 3RD FLOOR, OMAR DAOUK STREET

(Street)
 BEIRUT M8 2020-3313
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
[Pillar Pharmaceuticals 6, L.P.](#)
 (Last) (First) (Middle)
 PILLAR INVEST OFFSHORE SAL STARCO CTR,
 BLOC B, 3RD FLOOR, OMAR DAOUK STREET

(Street)
 BEIRUT M8 2020-3313
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
[Umari Abude](#)
 (Last) (First) (Middle)
 PILLAR INVEST OFFSHORE SAL STARCO CTR,
 BLOC B, 3RD FLOOR, OMAR DAOUK STREET

(Street)
 BEIRUT M8 2020-3313
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
[ZEIN YOUSSEF EL](#)
 (Last) (First) (Middle)
 PILLAR INVEST OFFSHORE SAL STARCO CTR,
 BLOC B, 3RD FLOOR, OMAR DAOUK STREET

(Street)
 BEIRUT M8 2020-3313
 (City) (State) (Zip)

Explanation of Responses:

1. On April 17, 2020, Pillar Partners Foundation, L.P. ("Pillar Foundation") distributed in-kind, without consideration, 46,304 shares of Common Stock to Abude Umari, in accordance with his pro rata interest in Pillar Foundation. This distribution was made in accordance with the exemptions under Rule 16a-9(a) and Rule 16a-13 of the Securities Exchange Act of 1934, as amended.
2. On April 17, 2020, Pillar Pharmaceuticals 6, L.P. ("Pillar 6") distributed in-kind, without consideration, 103,891 shares of Common Stock to Abude Umari, in accordance with his pro rata interest in Pillar 6. This distribution was made in accordance with the exemptions under Rule 16a-9(a) and Rule 16a-13 of the Securities Exchange Act of 1934, as amended.
3. Pillar Invest Corporation ("Pillar GP") is the general partner of Pillar Pharmaceuticals I, L.P., Pillar Pharmaceuticals II, L.P., Pillar Pharmaceuticals III, L.P., Pillar Pharmaceuticals IV, L.P., Pillar Pharmaceuticals V, L.P., Pillar 6 and Pillar Foundation (collectively, the "Pillar Funds"). Youssef El Zein and Abude Umari are directors of Pillar GP. Each of Pillar GP, Mr. El Zein and Mr. Umari disclaims Section 16 beneficial ownership of the securities beneficially owned by the Pillar Funds and this report shall not be deemed an admission that any of Pillar GP, Mr. El Zein or Mr. Umari is the Section 16 beneficial owner of any such securities, except to the extent of its or his pecuniary interest therein, if any, by virtue of its or his ownership interest in the Pillar Funds or Pillar GP, as applicable.
4. Includes the shares received by Mr. Umari in the distributions reported in footnotes (1) and (2).

Remarks:

<u>Pillar Invest Corporation, /s/ Youssef El Zein, Authorized Person</u>	<u>09/04/2020</u>
<u>Pillar Partners Foundation, L.P., /s/ Youssef El Zein, Authorized Person</u>	<u>09/04/2020</u>
<u>Pillar Pharmaceuticals, 6, L.P., /s/ Youssef El Zein, Authorized Person</u>	<u>09/04/2020</u>
<u>/s/ Abude Umari</u>	<u>09/04/2020</u>
<u>/s/ Youssef El Zein</u>	<u>09/04/2020</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.